secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-275862
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vor Biopharma announces $100M public offering of 10M shares at $10 each to fund telitacicept development
--------------------------------------------------------------------------------

- 10,000,000 shares at $10.00 each; expected net proceeds ~$93.7M (or $107.8M if underwriters' option fully exercised).
- Proceeds to advance telitacicept clinical development including Phase 3 trial for primary Sjögren's Disease, plus manufacturing/pre-commercialization.
- Offering expected to close November 12, 2025; underwriters have 30-day option for up to 1,500,000 additional shares.
- As of Sept 30, 2025, outstanding shares were 9,026,922; offering represents ~111% dilution if fully exercised.
- Company believes current cash plus proceeds will fund operations into Q2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312525275862/0001193125-25-275862-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312525275862/vor-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-275862

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer